Examination of the prevalence of high-risk human papillomavirus genotypes among women on the territory of Belgrade
References
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Fer-lay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020; 8(2): e191–203.
Su P, Ma J, Yu L, Tang S, Sun P. Clinical significance of ex-tended high-risk human papillomavirus genotyping and viral load in cervical cancer and precancerous lesions. Gy-necol Obstet Clin Med 2023; 3(1): 22–9.
Moussavou PB, Koumakpayi IH, Nkili-Meyong AA, Labouba I, Bisvigou U, Chansi JK, et al. Molecular analysis of human Papillomavirus detected among women positive for cervi-cal lesions by visual inspection with acetic acid/Lugol’s iodine (VIA/VILI) in Libreville, Gabon. Infect Agent Cancer 2016; 11(1): 50.
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epi-demiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 2015; 33(29): 3235–42.
Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70–9.
Moussavou-Boundzanga P, Koumakpayi IH, Labouba I, Leroy EM, Belembaogo E, Berthet N. Human papillomavirus detec-tion using the Abbott RealTime high-risk HPV tests compared with conventional nested PCR coupled to high-throughput sequencing of amplification products in cervical smear specimens from a Gabonese female popula-tion. Virol J 2017; 14(1): 241.
Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer 2020; 123(4): 510–7.
World Health Organization. WHO recommends DNA test-ing as a first-choice screening method for cervical cancer prevention [Internet]. World Health Organization; 2021 [accessed on: 2023 December 25]. Available from: https://www.who.int/europe/news/item/11-09-2021-who-recommends-dna-testing-as-a-first-choice-screening-method-for-cervical-cancer-prevention
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical prac-tice. Lancet Oncol 2011; 12(7): 663–72. Erratum in: Lancet Oncol 2011; 12(8): 722.
Martin CM, O'Leary JJ. Histology of cervical intraepithelial neoplasia and the role of biomarkers. Best Pract Res Clin Obstet Gynaecol 2011; 25(5): 605–15.
Bzhalava D, Eklund C, Dillner J. International standardiza-tion and classification of human papillomavirus types. Vi-rology 2015; 476: 341–4.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1–636.
Bioron diagnostics. RealLine DNA – Express [Internet]. BIORON Diagnostics GmbH; 2022 [accessed on: 2023 December 25]. Available from: https://www.bioron.
de/wpcontent/uploads/2022/10/B_2IFU.Express_VBC8899-R_Rev01_1022_EN_GLU.pdf
ThermoFisher Scientific. KingFisher Duo Prime Purification System [Internet]. Thermo Fisher Scientific Inc; 2022 [ac-cessed on: 2023 December 25]. Available from: https://assets.thermofisher.com/TFS-Assets/BID/brochu
res/kingfisher-duo-prime-purification-system-brochure.pdf
CerTest. VIASURE Real Time PCR Detection Kits – High Risk Papilloma [Internet]. Spain: Certest Biotec SL [ac-cessed on: 2023 December 25]. Available from: https://www.certest.es/products/high-risk-papilloma/